Device Trial Radar · NCT04031040
A Post-market Clinical Follow up of the Genio® System for the Treatment of Obstructive Sleep Apnea in Adults
Last checked: Nov 20, 2026Latest source record: Mar 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
110
Planned (sponsor's estimate)
Start
Sep 1, 2019
Primary completion
Oct 30, 2026
Study completion Oct 2030
Sponsor
- Lead sponsor
- Nyxoah S.A.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 24, 2019
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to confirm the safety and clinical effectiveness of the Genio® system in moderate to severe Obstructive Sleep Apnea (OSA) adult patients over a period of 5 years post-surgery.
Conditions
- Obstructive Sleep Apnea
Interventions
Genio® system therapyDevice
Hypoglossal nerve stimulation system
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of device-related Serious Adverse Events (SADEs)Time frame: 12 months post-surgery
- Change in Apnea-Hypopnea Index from baselineTime frame: 12 months post-surgery
- Change in the quality of life measured by the Functional Outcomes of Sleep QuestionnaireTime frame: 12 months post-surgery
Locations
19 sites in 5 countries. Site status is shown where the registry gives one.
Ziekenhuis Netwerk Antwerpen - ZNA Jan Palfijn
Antwerp, Belgium
Universitair Ziekenhuis Antwerpen
Antwerp, Belgium
CHU - Angers
Angers, France
16 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.